Track topics on Twitter Track topics that are important to you
Robert Robertson AvenueThe Oxford Science Park
OX4 4 GA
Phone: +44 1865 783 000
Fax: +44 1865 783 001
UK gene cell therapy designer Oxford BioMedica’s shares jumped as much as 11.2% to 12.30 pence this…
Biopharmaceutical firm Axovant Sciences has agreed exclusive worldwide rights for the development and commercialisation of gene therapy company Oxford BioMedica’s...Read More... The post Axovant buy...
Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrate...
Innovate UK has awarded Oxford BioMedica a £3m grant to support the UK's efforts to produce viral vectors and ensure adequate supply to meet future demand.
Oxford BioMedica has been awarded a £3 million grant by the UK's innovation agency, Innovate UK, to support the UK's efforts to produce viral vectors and ensure adequate supply to meet future demand.
Bioverativ awarded a $100 million contract to the UK's Oxford BioMedica to develop lentiviral vectors for use in Bioverativ's -More-
Oxford BioMedica said today it will partner with Bioverativ to develop and manufacture lentiviral vectors designed to treat hemophilia, through a collaboration that could generate up to $105 million-p...
Oxford Biomedica intends to raise approximately £20.5m by way of a conditional placing of ordinary shares to raise money for expansion of bioprocessing facilities, the company said on Friday. The p.....
Growth retardation or chronic malnutrition (low height for age) indicates a failure in the natural genetic potential that allows us to growth.
The purpose of this scientific study is to clarify whether there is a relationship between the appearance of radiolucent lines in bone-cement interphase of the tibial component of the diff...
Comparison of two unicompartmental knee arthroplasties (UKA), to see if Sigma UKA performs equally good as the Oxford UKA. The study focuses on how well the arthroplasty is fixated to the ...
The purpose of this study is to collect information on complications and survivorship of patients implanted with the Oxford™ Meniscal Unicompartmental Knee System at multiple sites in th...
The objective of this study is to compare the effect on gait of unicompartmental knee arthroplasty (UKA), using the Oxford® Partial Knee, versus total knee arthroplasty (TKA), using the V...
Prospectively monitor the patients receiving the Oxford Partial knee arthroplasty
Oxford BioMedica advanced gene therapy techniques.
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the...
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was esta...
Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases (ID) such as AIDS, Lyme Disease, and Viral He...
Oxford Resource Partners, LP is a low cost producer of high value steam coal in Northern Appalachia and the Illinois Basin. Oxford markets its coal primarily to large electric utilities with coal-fir...
We have published hundreds of Oxford BioMedica news stories on BioPortfolio along with dozens of Oxford BioMedica Clinical Trials and PubMed Articles about Oxford BioMedica for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oxford BioMedica Companies in our database. You can also find out about relevant Oxford BioMedica Drugs and Medications on this site too.
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...